Merck plans to stop a late-stage study testing its drug to treat pulmonary arterial hypertension (PAH) ahead of time based on ...

Merck MRK has decided to stop the phase III HYPERION study early. The study evaluates MRK’s pulmonary arterial hypertension ...

Kennedy’s commitment to walk away from the potential windfall is a major reversal for the nominee, who in his ethics plan ...

Merck and Japan-based Eisai said on Friday a combination of their therapies failed to extend the lives of patients with a ...

Merck's blockbuster drug Keytruda and Eisai's cancer drug Lenvima, in combination with chemotherapy, failed to improve ...

If confirmed as health secretary, Robert F. Kennedy Jr. would oversee the Food and Drug Administration and other agencies ...

Morgan Stanley analyst Terence Flynn has maintained their neutral stance on MRK stock, giving a Hold rating yesterday.Invest with Confidence: ...

Senators had objected to the financial conflict posed by Robert F. Kennedy Jr.’s decision to retain a financial stake in ...

Several medicines are poised to reach new heights after winning key endorsements from European drug regulators. | Among those ...

All patients in the trial will have the opportunity to resume or begin treatment with Winrevair, the company said.

As its shares pop in Friday's session, pharmaceutical giant AbbVie Inc. (ABBV) posted a fourth quarter revenue beat and raised its long-term sales guidance for new drugs Skyrizi and Rinvoq by $4 ...

Discover why Merck presents a compelling long-term investment opportunity with its discounted valuation, robust pipeline, and ...